89Bio Earnings Reports

89bio reported a net loss of $118.4 million for the three months ended December 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $440.0 million as of December 31, 2024. The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expected in 1Q 2026.

89bio reported a net loss of $149.1 million for the third quarter of 2024, driven by increased R&D expenses related to Phase 3 clinical trials and milestone payments. The company's cash, cash equivalents, and marketable securities totaled $423.8 million as of September 30, 2024.

89bio reported a net loss of $48.0 million for the second quarter ended June 30, 2024. The increase in net loss was primarily attributable to increased R&D expenses to advance the company’s Phase 3 clinical trials, increased G&A expenses associated with higher headcount, and expenses to support the Company’s expanded operations.

89bio reported a net loss of $51.7 million for the first quarter of 2024. The company initiated the Phase 3 ENLIGHTEN-Fibrosis trial and expects to initiate the ENLIGHTEN-Cirrhosis trial this quarter. They also received PRIME status from the EMA for pegozafermin in MASH treatment.

89bio reported a net loss of $40.2 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $578.9 million as of December 31, 2023. The company is advancing its Phase 3 trials in NASH and SHTG.

89bio reported a net loss of $34.7 million for the third quarter ended September 30, 2023. As of September 30, 2023, the company's cash, cash equivalents and short-term available-for-sale securities totaled $448.3 million. The FDA granted Breakthrough Therapy Designation to pegozafermin for NASH with fibrosis.

89bio reported a net loss of $38.4 million for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and short-term available-for-sale securities totaled $478.0 million as of June 30, 2023. The company initiated ENTRUST, the Phase 3 trial of pegozafermin in patients with SHTG.

89bio reported positive topline results from the ENLIVEN Phase 2b trial of pegozafermin in NASH, demonstrating high statistical significance on both primary histology endpoints. The company completed an underwritten public offering with $316.2 million in gross proceeds and had a cash balance of $480.9 million as of March 31, 2023.

89bio reported a net loss of $24.6 million for the three months ended December 31, 2022. As of December 31, 2022, the company had cash, cash equivalents, and short-term investments totaling $188.2 million.

89bio reported a net loss of $26.8 million for the third quarter ended September 30, 2022. The company's cash, cash equivalents, and short-term investments totaled $193.3 million as of September 30, 2022. Enrollment was completed in the ENLIVEN Phase 2b NASH trial, with topline data expected in Q1 2023.

89bio reported positive topline results from the ENTRIGUE Phase 2 trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) and strengthened financial resources, raising approximately $94.5 million in gross proceeds through an underwritten offering.

89bio reported a net loss of $25.6 million for the first quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $126.1 million as of March 31, 2022, which is expected to fund operations into the second half of 2023.

89Bio reported positive topline data from its Phase 1b/2a NASH trial and closed enrollment in the Phase 2 ENTRIGUE trial in SHTG. The company's cash, cash equivalents, and short-term investments totaled $150.7 million as of December 31, 2021.

89bio reported a net loss of $28.3 million for the third quarter of 2021. The company's R&D expenses were $23.6 million, and G&A expenses were $4.6 million. As of September 30, 2021, 89bio had cash, cash equivalents, and short-term investments of $157.4 million.

89bio reported a net loss of $20.7 million for the quarter ended June 30, 2021. The company had cash, cash equivalents, and short-term investments of $171.0 million as of June 30, 2021. The company initiated Phase 2b ENLIVEN trial in NASH patients and completed enrollment in NASH histology cohort.

89bio reported its Q1 2021 financial results, highlighting the FDA's written guidance on the Phase 2b ENLIVEN trial design for NASH and a cash position of $189.6 million as of March 31, 2021.

89bio reported cash, cash equivalents, and short-term investments totaling $204.7 million as of December 31, 2020. R&D expenses were $8.8 million for the three months ended December 31, 2020, and G&A expenses were $3.8 million for the same period. The company anticipates important clinical milestones in 2021 to validate BIO89-100's potential in NASH and SHTG.

89bio reported a net loss of $14.6 million for the third quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $219.2 million as of September 30, 2020. They also initiated their Phase 2 trial in SHTG and in NASH they announced impressive results from their Phase 1b/2a trial.

89bio reported a net loss of $10.5 million for the first quarter of 2020. The company's cash and cash equivalents were $85.5 million as of March 31, 2020. Topline results from the Phase 1b/2a NASH trial are expected in the second half of 2020, and the FDA cleared the IND application for SHTG.

89bio reported its Q4 and full year 2019 financial results, noting the initiation of the Phase 1b/2a clinical trial for BIO89-100 in NASH, planned initiation of Phase 2 study in SHTG, and the completion of an upsized initial public offering.